Methylphenidate /kg

PreclinicalSmall molecule

Methylphenidate /kg is one of 36 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

Attention Deficit Hyperactivity DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Attention Deficit Hyperactivity Disorder

#DrugCompanyPhaseTrials

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

2 2

Ambien

PPurdue Pharma LP

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Catapres

Boehringer Ingelheim

Phase 3

1 5

OROS Oxybutynin

Johnson & Johnson

Phase 3

4 6

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 7

Ritalin

Pfizer

Phase 3

5 8

Cymbalta

Alnylam Pharmaceuticals

Phase 2

1 9

Adderall-XR

NNew River Pharmaceuticals

Phase 3

2 10

Concerta

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalActive, not recruiting

Medication

NCT05469386

Clinical

Trials by Indication[1]

Medication1 trial

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

Active, not recruiting·FFlorida International University·Phase 4·NCT05469386·288 enrolled

Attention Deficit Hyperactivity Disorder1 trial

Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Completed·FFlorida International University·N/A·NCT00050622·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Methylphenidate /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methylphenidate /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methylphenidate /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Florida International University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFlorida International University

Methylphenidate /kg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Medication1 trial

Attention Deficit Hyperactivity Disorder1 trial

References

Drug Info

Quick Facts

Related News